Sudha Patnaik, MD
General Practice · Philadelphia, PANPI 1679509855
Payments from drug & device makers
Across 27 payments — averaging $20.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$136
- GSK$83
- Lilly USA, LLC$74
- Novo Nordisk$64
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$37
- Teva Pharmaceuticals USA, Inc.$32
- plus $138 from 8 others
What the payments were for
- Food & beverage$562100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 5 | $136 |
| GSK | 4 | $83 |
| Lilly USA, LLC | 3 | $74 |
| Novo Nordisk | 3 | $64 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $37 |
| Teva Pharmaceuticals USA, Inc. | 2 | $32 |
| Optinose US, Inc. | 1 | $26 |
| Pfizer | 1 | $22 |
| Kaleo, Inc. | 1 | $19 |
| Gilead | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Johnson & Johnson | 1 | $14 |
| Sunovion Pharmaceuticals Inc. | 1 | $12 |
| Amarin Pharma, Inc. | 1 | $12 |
How this compares
$562 in reported general payments places this provider in the 75th percentile of 3,208 general practice providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 12 | $2,000 |
| Omega-3 Acid Ethyl Esters | 15 | $1,945 |
| Atorvastatin Calcium | 116 | $1,295 |
| Ventolin HfaAlbuterol Sulfate | 13 | $809 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 25 | $697 |
| Ultra-Fine Micro Pen NeedlePen Needle, Diabetic | 12 | $660 |
| Omeprazole | 35 | $618 |
| Metformin Hcl | 58 | $607 |
| Fluticasone Propionate | 28 | $380 |
| Amlodipine Besylate | 68 | $380 |
| Simvastatin | 35 | $315 |
| Lisinopril | 56 | $310 |
| Metoprolol Succinate | 25 | $298 |
| Tamsulosin Hcl | 11 | $222 |
| Potassium Chloride | 11 | $203 |
Paid to pharmacies, not to this prescriber.
Other general practice in Philadelphia
- Corey AnolikPhiladelphia$2.1M
- Alan AtlasPhiladelphia$486K
- Marc ManosPhiladelphia$85K
- Joseph PreziosiPhiladelphia$18K
- Mark WolffPhiladelphia$13K
- Jordan BowerPhiladelphia$13K
- Leonard TauPhiladelphia$12K
- Stephen WilfredPhiladelphia$6K
- Jeffrey GazzaraPhiladelphia$6K
- Richard NagelbergPlymouth Meeting$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.